Silicon Valley Capital Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Silicon Valley Capital Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$197	Buy	+84	New	+$217	﹤0.01%	404

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Silicon Valley Capital Partners's ZNTL Position: Q1 2026 in Review

Silicon Valley Capital Partners opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 84 shares worth $197. The stake represents ﹤0.01% of the portfolio and ranks #404 among its holdings.

102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Silicon Valley Capital Partners held 84 shares of Zentalis Pharmaceuticals worth $197 as of Q1 2026.
Zentalis Pharmaceuticals was a new Silicon Valley Capital Partners position in Q1 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of Silicon Valley Capital Partners's portfolio in Q1 2026, its #404 holding.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Silicon Valley Capital Partners's 13F filing for Q1 2026, filed 19 May 2026.